Sage Therapeutics Inc (SAGE) reports significant growth in ZURZUVAE prescriptions and collaboration revenue, alongside a ...

Welcome to SAGE Therapeutics first quarter 2025 financial results conference call. (Operator Instructions). This call is being webcast live on the investors and media section of Sage's website at ...

Sage Therapeutics reported strong Q1 2025 growth, with ZURZUVAE leading the charge in postpartum depression treatment.

Kemper Corporation today announced that after the markets close on Wednesday, May 7, Kemper intends to issue its first quarter 2025 earnings release, financial supplement, and Form 10-Q. Following ...

Visa today announced its fiscal second quarter 2025 financial results through an earnings release that will be furnished with the Securities and Exchange Commission on a Form 8-K and available on its ...